Shares of Radius Health Inc (NASDAQ:RDUS) have earned an average rating of “Hold” from the twelve analysts that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, six have given a hold rating and five have given a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $52.00.
A number of equities research analysts have issued reports on the company. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $58.00 price target on shares of Radius Health in a research report on Thursday. BidaskClub raised Radius Health from a “sell” rating to a “hold” rating in a research report on Wednesday, January 10th. Zacks Investment Research raised Radius Health from a “sell” rating to a “hold” rating in a research report on Monday, January 8th. Citigroup assumed coverage on Radius Health in a research report on Wednesday, December 6th. They issued a “neutral” rating and a $30.00 price target on the stock. Finally, ValuEngine raised Radius Health from a “strong sell” rating to a “sell” rating in a research report on Friday, December 1st.
In other Radius Health news, VP Brent Hatzis-Schoch bought 1,778 shares of the business’s stock in a transaction dated Friday, November 10th. The shares were acquired at an average price of $28.09 per share, with a total value of $49,944.02. Following the transaction, the vice president now owns 2,278 shares of the company’s stock, valued at $63,989.02. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Growth N. V. Biotech bought 50,000 shares of the business’s stock in a transaction dated Wednesday, October 25th. The shares were acquired at an average cost of $32.85 per share, for a total transaction of $1,642,500.00. Following the transaction, the insider now directly owns 5,548,799 shares in the company, valued at approximately $182,278,047.15. The disclosure for this purchase can be found here. Insiders have bought a total of 158,578 shares of company stock worth $4,659,916 in the last three months. Corporate insiders own 15.00% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the company. Cubist Systematic Strategies LLC acquired a new stake in shares of Radius Health during the 3rd quarter worth about $110,000. Ameritas Investment Partners Inc. raised its position in shares of Radius Health by 19.9% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,266 shares of the biopharmaceutical company’s stock worth $148,000 after acquiring an additional 541 shares in the last quarter. Advisor Group Inc. raised its position in shares of Radius Health by 267.2% during the 2nd quarter. Advisor Group Inc. now owns 3,969 shares of the biopharmaceutical company’s stock worth $180,000 after acquiring an additional 2,888 shares in the last quarter. Amalgamated Bank acquired a new stake in shares of Radius Health during the 2nd quarter worth about $211,000. Finally, Principal Financial Group Inc. raised its position in shares of Radius Health by 14.1% during the 2nd quarter. Principal Financial Group Inc. now owns 6,809 shares of the biopharmaceutical company’s stock worth $308,000 after acquiring an additional 839 shares in the last quarter.
Radius Health (NASDAQ:RDUS) opened at $36.12 on Friday. Radius Health has a twelve month low of $24.66 and a twelve month high of $49.16. The company has a market capitalization of $1,509.88, a PE ratio of -6.65 and a beta of 1.10. The company has a current ratio of 12.87, a quick ratio of 12.79 and a debt-to-equity ratio of 0.53.
Radius Health (NASDAQ:RDUS) last posted its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.03). The business had revenue of $13.50 million during the quarter, compared to the consensus estimate of $6.90 million. During the same quarter in the prior year, the company earned ($1.07) earnings per share. equities analysts anticipate that Radius Health will post -5.57 earnings per share for the current fiscal year.
Radius Health Company Profile
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.